In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Integra Lifesciences Holdings Corp (NASDAQ: IART) closed at $21.82 down -1.62% from its previous closing price of $22.18. In other words, the price has decreased by -$1.62 from its previous closing price. On the day, 0.87 million shares were traded. IART stock price reached its highest trading level at $22.35 during the session, while it also had its lowest trading level at $21.49.
Ratios:
For a deeper understanding of Integra Lifesciences Holdings Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 67.50. For the most recent quarter (mrq), Quick Ratio is recorded 0.71 and its Current Ratio is at 1.17. In the meantime, Its Debt-to-Equity ratio is 1.28 whereas as Long-Term Debt/Eq ratio is at 0.88.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on December 02, 2024, initiated with a Underweight rating and assigned the stock a target price of $20.
Citigroup Downgraded its Neutral to Sell on July 30, 2024, whereas the target price for the stock was revised from $30 to $23.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 03 ’24 when Schwartz Eric sold 4,070 shares for $24.59 per share. The transaction valued at 100,102 led to the insider holds 59,511 shares of the business.
Schwartz Eric bought 4,070 shares of IART for $100,102 on Dec 03 ’24. On Dec 02 ’24, another insider, McBreen Michael J., who serves as the EVP & President, CSS of the company, sold 1,700 shares for $24.16 each. As a result, the insider received 41,064 and left with 56,182 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IART now has a Market Capitalization of 1712715008 and an Enterprise Value of 3397741824. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.05 while its Price-to-Book (P/B) ratio in mrq is 1.09. Its current Enterprise Value per Revenue stands at 2.11 whereas that against EBITDA is 10.524.
Stock Price History:
The Beta on a monthly basis for IART is 1.26, which has changed by -0.36319268 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, IART has reached a high of $35.49, while it has fallen to a 52-week low of $16.81. The 50-Day Moving Average of the stock is -8.22%, while the 200-Day Moving Average is calculated to be -6.45%.
Shares Statistics:
For the past three months, IART has traded an average of 650.17K shares per day and 667260 over the past ten days. A total of 77.17M shares are outstanding, with a floating share count of 66.12M. Insiders hold about 14.38% of the company’s shares, while institutions hold 90.52% stake in the company. Shares short for IART as of 1741910400 were 3978327 with a Short Ratio of 6.12, compared to 1739491200 on 3504670. Therefore, it implies a Short% of Shares Outstanding of 3978327 and a Short% of Float of 5.9799999999999995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Integra Lifesciences Holdings Corp (IART) is currently drawing attention from 10.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.57, with high estimates of $0.64 and low estimates of $0.51.
Analysts are recommending an EPS of between $2.5 and $2.44 for the fiscal current year, implying an average EPS of $2.46. EPS for the following year is $2.72, with 11.0 analysts recommending between $2.85 and $2.67.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $381.17M this quarter.It ranges from a high estimate of $385M to a low estimate of $379.29M. As of the current estimate, Integra Lifesciences Holdings Corp’s year-ago sales were $368.87MFor the next quarter, 10 analysts are estimating revenue of $417.04M. There is a high estimate of $425.89M for the next quarter, whereas the lowest estimate is $409.2M.
A total of 11 analysts have provided revenue estimates for IART’s current fiscal year. The highest revenue estimate was $1.69B, while the lowest revenue estimate was $1.67B, resulting in an average revenue estimate of $1.68B. In the same quarter a year ago, actual revenue was $1.61BBased on 11 analysts’ estimates, the company’s revenue will be $1.75B in the next fiscal year. The high estimate is $1.77B and the low estimate is $1.72B.
